Analysis of selected malignant tumours in Bielsko-Biala in the year 2015
Department of Natural Sciences, University of Silesia, Sosnowiec, Poland
Correspondence: Dariusz Góra, Iłownica 75, 43-394 Rudzica, Poland, tel.: +48 507 194 677, e-mail:
Pediatr Med Rodz 2019, 15 (4), p. 398–402
DOI: 10.15557/PiMR.2019.0068

Introduction: In 2015, 163,281 new cases of malignant tumours were registered in Poland, with 81,649 cases in men and 81,632 cases in women. In the province of Silesia, there were 19,180 new cases: 9,567 in men and 9,613 in women (absolute numbers). In the Beskid Oncology Centre – John Paul II Municipal Hospital, there were 430 cases of malignant tumours in men and 403 in women. Aim of the study: This study presents the incidence of selected malignant neoplasms among the residents of the city of Bielsko-Biala, who were hospitalised in the above mentioned hospital in 2015. Material and methods: Statistical data in the form of the annual report for 2015 were received from the Beskid Oncology Centre – John Paul II Municipal Hospital in Bielsko-Biala, Poland. The statistical analysis concerned breast cancer, testicular cancer and prostate cancer. Results and discussion: In the Beskid Oncology Centre – John Paul II Municipal Hospital in Bielsko-Biala, there were 7 cases of malignant testicular cancer and 80 cases of prostate gland carcinoma in 2015. In women, there were 90 malignant breast cancer cases, and it was the most frequent cancer in the discussed hospital. The vast majority of the reported cancers of various types occurred in the group of people, both men and women, over 60 years of age. Conclusions: Cancer is a serious health problem in both Poland and worldwide. In Poland, cancer is the second cause of death in general and the first cause of death among patients at the age below 65 years. The analysis of the data showed that, in the city of Bielsko-Biala, cancers of the breast and prostate gland belong to the group of the most common malignant tumours.

Keywords: epidemiology of cancer, neoplasm, prostate cancer